Don’t miss the latest developments in business and finance.

Jubilant Life Sciences receives ANDA final approval for Felodipine ER Tablets

Image
Capital Market
Last Updated : Aug 25 2016 | 9:47 AM IST

From USFDA

Jubilant Life Sciences has announced that it has received Abbreviated New Drug Application (ANDA) final approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg, the generic version of Plendil Tablets of AstraZeneca, which is used for the treatment of hypertension.

As on June 30, 2016, Jubilant Life Sciences had a total of 770 filings for Oral Solids of which 578 have been approved in various regions globally. This includes 70 ANDAs filed in the US, of which 44 have been approved and 104 filings in Europe.

Powered by Capital Market - Live News

Also Read

First Published: Aug 25 2016 | 9:15 AM IST

Next Story